Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just reading about recent acquisition when suddenly..

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Jan 17, 2021 12:01pm

257 Views

Post# 32315468

RE:RE:Just reading about recent acquisition when suddenly..

Hey 3b......and what kinda market cap would that fetch.......tightening my seatbelt........=3burtc]If Bayer did the licensing deal, at 15 % ( industry standard ), and with name recognition, I think 1 billion in revenue for Antibe is closer than what's expected. Glta, nothing but blue skies! P.s. I loved Fridays news lol.[/quote]

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide